Y-Mabs Therapeutics Inc (YMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2020 | 03-2020 | 12-2019 | 09-2019 | 06-2019 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -66,572 | -26,179 | -81,028 | -57,892 | -33,970 |
| Depreciation Amortization | 186 | 86 | 166 | 87 | 39 |
| Accounts payable and accrued liabilities | 1,305 | 1,740 | 2,617 | 1,031 | 3,015 |
| Other Working Capital | 3,689 | 2,101 | 2,665 | 5,584 | 4,584 |
| Other Operating Activity | 12,001 | 496 | 2,083 | 2,272 | -1,191 |
| Operating Cash Flow | $-49,391 | $-21,756 | $-73,497 | $-48,918 | $-27,523 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -28 | -26 | -1,965 | -818 | -201 |
| Investing Cash Flow | $-28 | $-26 | $-1,965 | $-818 | $-201 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 370 | 370 | 134,704 | N/A | N/A |
| Financing Cash Flow | $370 | $370 | $134,704 | $N/A | $N/A |
| Exchange Rate Effect | -28 | 50 | 23 | 57 | 16 |
| Beginning Cash Position | 207,136 | 207,136 | 147,871 | 147,871 | 147,871 |
| End Cash Position | 158,059 | 185,774 | 207,136 | 98,192 | 120,163 |
| Net Cash Flow | $-49,077 | $-21,362 | $59,265 | $-49,679 | $-27,708 |
| Free Cash Flow | |||||
| Operating Cash Flow | -49,391 | -21,756 | -73,497 | -48,918 | -27,523 |
| Capital Expenditure | -28 | -26 | -1,965 | -818 | -201 |
| Free Cash Flow | -49,419 | -21,782 | -75,462 | -49,736 | -27,724 |